Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ctDNA Monitoring with Sacituzumab Tirumotecan in EGFR-Mutated NSCLC After EGFR-TKI Failure
ChiCTR2600115950Phase 4Not yet recruiting
- Sponsor
- Shaanxi Cancer Hospital
- Start
- Jan 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of sacituzumab tirumotecan in Non-small cell lung cancer (NS-NSCLC), sponsored by Shaanxi Cancer Hospital. Primary endpoint: Circulating tumor DNA (ctDNA). Planned start Jan 2026; status: not yet recruiting.
02
Drugs
sacituzumab tirumotecan
03
Conditions
Non-small cell lung cancer (NS-NSCLC)
Beyond the preview
Go deeper on ChiCTR2600115950.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600115950.